News and Updates

Upcoming Events

Cancer Advances Representatives will be attending these upcoming industry events:







Press Releases, Updates, and Annoucements




July 15, 2013
Cancer Advances Announces Allowance of a New Patent to Its Suite of Gastrin Inhibitor Products PDF

April 15, 2013
Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products PDF

July 31, 2012
Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the issuance of a new patent for a companion diagnostic 

September 20, 2011
Cancer Advances Presenting at NCI Conference 

September 7, 2009- Abstract accepted for presentation at EORTC-NCI-ASCO Annual Meeting
The abstract entitled "Immune response to gastrin-17 is an independent covariate for improved survival in gastrointestinal cancers" has been accepted for presentation at the European Organisation for Research and Treatment of Cancer - National Cancer Institute - American Society of Clinical Oncology Annual Meeting (entitled “Molecular Markers in Cancer”). The meeting will take place October 15-17, 2009 in Brussels, Belgium. The presentation is scheduled for October 16, 2009.

August 5, 2009 - Abstract accepted for presentation at DIA's 22nd Annual EuroMeeting
Cancer Advances announces the abstract entitled "Back to the basics: Capitalizing on novel approaches for establishing prospective diagnostics in clinical oncology development" has been accepted for presentation at the Drug Information Association's 22nd Annual EuroMeeting. The meeting will take place March 8-10, 2010 in Monaco. Representatives of Cancer Advances will be attending the meeting and presenting on the topic.

July 21, 2009 - Abstract accepted for ECCO 15 - 34th ESMO Multidisciplinary Congress
Cancer Advances announces the abstract entitled "Immune response to gastrin-17 is an independent covariate for survival in colorectal, gastric and pancreatic cancers" has been accepted for poster presentation at the ECCO 15 - 34th ESMO Multidisciplinary Congress. The joint meeting between the European Cancer Organisation and the European Society for Medical Oncology takes place September 20-24, 2009 in Berlin, Germany. The abstract will be published in the ECCO 15 - ESMO 34 Abstract Book with the European Journal of Cancer Supplement. Representatives from Cato Research and Cancer Advances will be attending this conference and presenting on this topic September 23, 2009.

July 13, 2009 - Abstract accepted for presentation at BIT Life Sciences' Annual Congress and Expo
Cancer Advances announces the abstract entitled "From bench to bedside: Challenges in bringing novel immuno therapeutic therapies from experimental studies into successful clinical programs" has been accepted for presentation at the BIT Life Sciences' 2nd Annual Congress and Expo of Molecular Diagnostics-2009. The presentation is scheduled for November 20th. The conference takes place November 19-21, 2009 in Beijing, China.

January 2, 2009
Cancer Advances Acquires the Technology and Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers

Related Items of Interest

Immune therapies improve treatment of cancers
The revolution is here, it's ongoing and it's bursting out of melanoma into solid tumors," said Steven O'Day,  This meeting [ASCO] is evidence of further progress in melanoma and in other very difficult to treat solid cancers. More...


Gastrin: from pathophysiology to cancer prevention and treatment.
Gastrin has been identified as the principal effector of gastric secretion, but several studies have demonstrated its role as a biomarker of cancer risk and as a growth factor for colorectal, stomach, liver, and pancreatic cancer. More...


Risk Predictor for Pancreatic Cancer
A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer More...


Pancreatic Cancer Patient's Inspirational Last Speech
Inspirational Speech by Dr Randy Pausch On the Oprah Winfrey Show More...